Validation of the Apnea Test Performed by High-flow Oxygen Therapy in Patients With Clinical Brain Death (APNEAFLOW)
Brain Death
About this trial
This is an interventional diagnostic trial for Brain Death focused on measuring Clinical brain death, Apnea test, High-flow oxygenation, Standard oxygen therapy, High-flow oxygen therapy
Eligibility Criteria
Inclusion Criteria: All patients in critical care with clinical brain death and potential organ and tissue donors for whom an apnea test is indicated. Exclusion Criteria: Minor patients. Person under guardianship Protected Majors Not affiliated to French social security Pregnant women. Patients with a history of Chronic Obstructive Pulmonary Disease with a GOLD score of III or IV. Patients with at least one absolute contraindication to organ donation. Patients whose relatives have spontaneously expressed the patient's refusal to donate organs for therapeutic purposes. Patients on VA ECMO and, in general, any patient with a contraindication to performing the apnea test (DV, significant hemodynamic instability...). Patients whose relatives have refused the patient's participation in the study.
Sites / Locations
- CHR d'ORLEANSRecruiting
Arms of the Study
Arm 1
Other
Clinical brain death
The protocol is based on performing two consecutive apnea tests on a patient in clinical brain death in intensive care unit. The first apnea test will be conducted under standard oxygen therapy and confirms clinical brain death (standard procedure). The second apnea test (for the study) will be conducted under high-flow oxygen therapy. Only patients whose apnea test is initially validated under standard oxygen therapy will have the second apnea test under high-flow oxygen therapy.